Spots Global Cancer Trial Database for physiological effects of drugs
Every month we try and update this database with for physiological effects of drugs cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo | NCT01512173 | Infantile Heman... | propranolol gel Placebo | 35 Days - 150 Days | Pierre Fabre Dermatology | |
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo | NCT01512173 | Infantile Heman... | propranolol gel Placebo | 35 Days - 150 Days | Pierre Fabre Dermatology | |
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
ADC-1013 First-in-Human Study | NCT02379741 | Neoplasms Solid Tumors | ADC-1013 | 18 Years - | Alligator Bioscience AB | |
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
Automated Telephone Monitoring for Symptom Management | NCT00799084 | Carcinoma | Nurse AVR | 21 Years - | Michigan State University | |
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
Pain and Fatigue Study | NCT00006253 | Carcinoma | Nurse Non-nurse coach | 21 Years - | Michigan State University | |
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer | NCT02385617 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | NCT05768139 | Breast Cancer Gynecologic Can... HNSCC Solid Tumors, A... | STX-478 Fulvestrant | 18 Years - | Scorpion Therapeutics, Inc. | |
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer | NCT05242874 | Chemotherapy-in... | Fosaprepitant ,... Fosaprepitant ,... | 18 Years - 70 Years | Henan Cancer Hospital | |
Vascular Function and Uterine Fibroids | NCT02123069 | Leiomyoma | Brachial artery... Acetylcholine Nitroprusside Norepinephrine Nitroprusside a... | 25 Years - 50 Years | Mayo Clinic | |
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | NCT04711109 | BRCA1 Mutation Breast Cancer Breast Diseases Breast Neoplasm... Breast Carcinom... Neoplasms | Denosumab Placebo Quality-of-Life... | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | NCT03933826 | Bladder Cancer Cancer of the B... Non-muscle Inva... | 18 Years - | University of Washington | ||
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | NCT00838578 | Colorectal Canc... | KRN330 Irinotecan | 18 Years - | Kyowa Kirin Co., Ltd. | |
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | NCT01384253 | Breast Neoplasm... Peritoneal Neop... Ovarian Neoplas... Pancreatic Neop... Stomach Neoplas... | ²¹²Pb-TCMC-Tras... trastuzumab | 19 Years - | Orano Med LLC | |
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D | NCT01166763 | Breast Cancer | vitamin D3 | - 55 Years | University of Kansas Medical Center | |
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | NCT01550510 | Stage IV Colore... | Ascorbic Acid Irinotecan | 18 Years - | Thomas Jefferson University | |
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery | NCT02256228 | Pain | Ropivacaine Saline | 18 Years - 74 Years | Göteborg University | |
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis | NCT01743560 | Oestrogen Recep... | RAD001 Exemestane | 18 Years - | Novartis | |
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
Study of AGEN2034 in Advanced Tumors and Cervical Cancer | NCT03104699 | Advanced Cancer Cervical Cancer | AGEN2034 | 18 Years - | Agenus Inc. | |
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | NCT03369223 | Advanced Cancer | BMS-986249 Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | NCT01550510 | Stage IV Colore... | Ascorbic Acid Irinotecan | 18 Years - | Thomas Jefferson University | |
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |